Ran BP-17 Activators
Ran BP-17 Activators are chemical compounds that enhance the functional activity of Ran BP-17, a Ran-binding protein that plays a critical role in the Ran GTPase cycle, an essential component of nucleocytoplasmic transport. The majority of these activators exert their influence by modulating protein phosphatases and kinases that directly regulate the phosphorylation state of Ran BP-17. Tautomycin, Okadaic Acid, Calyculin A, Phosphatase Inhibitor-2, and Cantharidin inhibit protein phosphatase 1 (PP1), thereby maintaining the phosphorylated, and hence activated, state of Ran BP-17.
Furthermore, Forskolin, IBMX, and 8-Br-cAMP enhance the functional activity of Ran BP-17 by increasing intracellular cAMP levels, leading to the activation of protein kinase A (PKA). PKA can phosphorylate RanBP-17, resulting in its activation. Similarly, H-89 and KT5720, potent inhibitors of PKA, prevent the inhibition of PKA, leading to enhanced phosphorylation and activation of Ran BP-17. Finally, Chelerythrine Chloride and Staurosporine, as inhibitors of protein kinase C (PKC), can enhance the activation of Ran BP-17 through a PKA-dependent pathway. These compounds collectively demonstrate the complex regulation of Ran BP-17 activation, emphasizing the delicate balance between phosphorylation and dephosphorylation in controlling Ran BP-17's functional activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). As Ran BP-17 can be dephosphorylated by PP1, inhibition of PP1 by Okadaic Acid can maintain the phosphorylated, and therefore activated, state of Ran BP-17. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is a potent inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). By inhibiting these phosphatases, Calyculin A can enhance the phosphorylation and activation of Ran BP-17. | ||||||
Cantharidin | 56-25-7 | sc-201321 sc-201321A | 25 mg 100 mg | $89.00 $279.00 | 6 | |
Cantharidin is a potent inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). Cantharidin, by inhibiting these phosphatases, can maintain the phosphorylated and thus activated state of Ran BP-17. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a potent adenylate cyclase activator that increases intracellular cAMP levels. Increased cAMP activates PKA, which can phosphorylate and activate Ran BP-17. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases (PDEs), raising intracellular cAMP levels. This increase in cAMP activates PKA, which can phosphorylate and activate Ran BP-17. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Br-cAMP is a cell-permeable cAMP analog that activates PKA. Activation of PKA can lead to the phosphorylation and activation of Ran BP-17. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
KT5720 is a potent and selective inhibitor of protein kinase A (PKA). By inhibiting PKA, KT5720 can enhance the phosphorylation and activation of Ran BP-17. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine Chloride is a potent, selective inhibitor of protein kinase C (PKC). Inhibition of PKC can lead to enhanced phosphorylation and activation of Ran BP-17 through a PKA-mediated pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. By inhibiting PKC, Staurosporine can enhance the phosphorylation and activation of Ran BP-17 via a PKA-dependent pathway. | ||||||